Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

8.785 -0.075 (-0.85%)
Streaming Delayed Price Updated: 3:12 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
From Certara
Via GlobeNewswire
News headline image
Certara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through... 
From Certara
Via GlobeNewswire
News headline image
Beyond The Numbers: 4 Analysts Discuss Certara Stock ↗
 
Via Benzinga
News headline image
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Decoding 4 Analyst Evaluations For Certara ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Certara ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Recap: Certara Q3 Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and... 
From Certara
Via GlobeNewswire
News headline image
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Launches Phoenix™ Version 8.5 Drug Development Software
From Certara
Via GlobeNewswire
News headline image
CERT Stock Earnings: Certara Misses EPS, Misses Revenue for Q2 2024 ↗
CERT stock results show that Certara missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
From Certara
Via GlobeNewswire
News headline image
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
From Certara
Via GlobeNewswire
News headline image
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Certara Appoints New Chief Human Resources Officer & General Counsel
From Certara
Via GlobeNewswire
News headline image
CERT Stock Earnings: Certara Meets EPS, Beats Revenue for Q1 2024 ↗
CERT stock results show that Certara met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Certara Reports First Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
From Certara
Via GlobeNewswire
News headline image
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Tax Season Is Here: Meet The New Federal Program That Can Eat Away At Tax Preparation Companies ↗
New IRS program launching for free tax filing could affect tax prep companies like H&R Block and Intuit. Market share drop could impact ETFs. 
Via Benzinga
News headline image
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. 
From Certara
Via GlobeNewswire
News headline image
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies 
From Certara
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.